IL109869A - Loracarb isopropenolate and the process of converting Loracrab isopropenolate to Loracrab monohydrate - Google Patents
Loracarb isopropenolate and the process of converting Loracrab isopropenolate to Loracrab monohydrateInfo
- Publication number
- IL109869A IL109869A IL109869A IL10986994A IL109869A IL 109869 A IL109869 A IL 109869A IL 109869 A IL109869 A IL 109869A IL 10986994 A IL10986994 A IL 10986994A IL 109869 A IL109869 A IL 109869A
- Authority
- IL
- Israel
- Prior art keywords
- loracarbef
- isopropanolate
- monohydrate
- crystalline
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 12
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 title claims description 22
- GPYKKBAAPVOCIW-HSASPSRMSA-N (6r,7s)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 GPYKKBAAPVOCIW-HSASPSRMSA-N 0.000 title abstract description 27
- 229960001977 loracarbef Drugs 0.000 title abstract description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 32
- 150000004682 monohydrates Chemical group 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 238000002441 X-ray diffraction Methods 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 abstract description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 229910001868 water Inorganic materials 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000000023 Kugelrohr distillation Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000004683 dihydrates Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D463/10—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D463/14—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hetero atoms directly attached in position 7
- C07D463/16—Nitrogen atoms
- C07D463/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
- C07D463/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D463/22—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/072,204 US5399686A (en) | 1993-06-04 | 1993-06-04 | Loracarbef isopropanolate and a process for converting loracarbef isopropanolate to loracarbef monohydrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL109869A0 IL109869A0 (en) | 1994-10-07 |
| IL109869A true IL109869A (en) | 1998-06-15 |
Family
ID=22106211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL109869A IL109869A (en) | 1993-06-04 | 1994-06-02 | Loracarb isopropenolate and the process of converting Loracrab isopropenolate to Loracrab monohydrate |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5399686A (pt) |
| EP (1) | EP0627429B1 (pt) |
| JP (1) | JP3442861B2 (pt) |
| KR (1) | KR100308746B1 (pt) |
| AT (1) | ATE178328T1 (pt) |
| BR (1) | BR9402148A (pt) |
| CA (1) | CA2124999C (pt) |
| DE (1) | DE69417472T2 (pt) |
| DK (1) | DK0627429T3 (pt) |
| ES (1) | ES2129106T3 (pt) |
| FI (1) | FI108133B (pt) |
| GR (1) | GR3030211T3 (pt) |
| HU (1) | HUT67911A (pt) |
| IL (1) | IL109869A (pt) |
| SI (1) | SI0627429T1 (pt) |
| TW (1) | TW492968B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399686A (en) * | 1993-06-04 | 1995-03-21 | Eli Lilly And Company | Loracarbef isopropanolate and a process for converting loracarbef isopropanolate to loracarbef monohydrate |
| US5550231A (en) * | 1993-06-15 | 1996-08-27 | Eli Lilly And Company | Loracarbef hydrochloride C1-C3 alcohol solvates and uses thereof |
| US5580977A (en) * | 1995-03-01 | 1996-12-03 | Eli Lilly And Company | Process for preparing loracarbef monohydrate |
| GB9717629D0 (en) | 1997-08-21 | 1997-10-22 | Johnson Matthey Plc | Removal of residual organic solvents |
| KR100519650B1 (ko) * | 1999-02-05 | 2005-10-07 | 제일모직주식회사 | 점도가 균일한 폴리아믹산의 제조방법 |
| CA2506872A1 (en) * | 2002-11-21 | 2004-06-03 | Ranbaxy Laboratories Limited | Monohydrate solvates of loracarbef |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3531481A (en) * | 1969-04-21 | 1970-09-29 | Lilly Co Eli | Method for manufacture of crystalline cephalosporin |
| US3502663A (en) * | 1969-04-21 | 1970-03-24 | Lilly Co Eli | Crystalline cephalosporin,method for its manufacture |
| US4775751A (en) * | 1985-06-03 | 1988-10-04 | Eli Lilly & Company | Process for cephalexin hydrochloride alcoholates |
| CA1334970C (en) * | 1987-10-06 | 1995-03-28 | Carol Elaine Pasini | Crystalline .beta.-lactam hydrate |
| CA2002596A1 (en) * | 1988-11-14 | 1990-05-14 | Thomas M. Eckrich | Hydrates of b-lactam antibiotic |
| US4977257A (en) * | 1988-11-14 | 1990-12-11 | Eli Lilly And Company | DMF solvates of a β-lactam antibiotic |
| US5352782A (en) * | 1993-06-04 | 1994-10-04 | Eli Lilly And Company | Process for preparing crystalline β-lactam monohydrate |
| US5399686A (en) * | 1993-06-04 | 1995-03-21 | Eli Lilly And Company | Loracarbef isopropanolate and a process for converting loracarbef isopropanolate to loracarbef monohydrate |
-
1993
- 1993-06-04 US US08/072,204 patent/US5399686A/en not_active Expired - Lifetime
-
1994
- 1994-06-01 AT AT94303942T patent/ATE178328T1/de not_active IP Right Cessation
- 1994-06-01 TW TW083105010A patent/TW492968B/zh not_active IP Right Cessation
- 1994-06-01 EP EP94303942A patent/EP0627429B1/en not_active Expired - Lifetime
- 1994-06-01 ES ES94303942T patent/ES2129106T3/es not_active Expired - Lifetime
- 1994-06-01 DE DE69417472T patent/DE69417472T2/de not_active Expired - Fee Related
- 1994-06-01 BR BR9402148A patent/BR9402148A/pt not_active Application Discontinuation
- 1994-06-01 DK DK94303942T patent/DK0627429T3/da active
- 1994-06-01 SI SI9430256T patent/SI0627429T1/xx not_active IP Right Cessation
- 1994-06-02 KR KR1019940012342A patent/KR100308746B1/ko not_active IP Right Cessation
- 1994-06-02 IL IL109869A patent/IL109869A/en not_active IP Right Cessation
- 1994-06-02 CA CA002124999A patent/CA2124999C/en not_active Expired - Fee Related
- 1994-06-03 JP JP12229794A patent/JP3442861B2/ja not_active Expired - Fee Related
- 1994-06-03 HU HU9401673A patent/HUT67911A/hu unknown
- 1994-06-03 FI FI942631A patent/FI108133B/fi not_active IP Right Cessation
- 1994-12-01 US US08/347,759 patent/US5672700A/en not_active Expired - Fee Related
-
1999
- 1999-05-13 GR GR990401296T patent/GR3030211T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9402148A (pt) | 1994-12-27 |
| JP3442861B2 (ja) | 2003-09-02 |
| DE69417472D1 (de) | 1999-05-06 |
| KR100308746B1 (ko) | 2001-11-30 |
| GR3030211T3 (en) | 1999-08-31 |
| HU9401673D0 (en) | 1994-09-28 |
| SI0627429T1 (en) | 1999-10-31 |
| US5672700A (en) | 1997-09-30 |
| IL109869A0 (en) | 1994-10-07 |
| TW492968B (en) | 2002-07-01 |
| HUT67911A (en) | 1995-05-29 |
| EP0627429B1 (en) | 1999-03-31 |
| DE69417472T2 (de) | 1999-08-19 |
| EP0627429A1 (en) | 1994-12-07 |
| ATE178328T1 (de) | 1999-04-15 |
| US5399686A (en) | 1995-03-21 |
| DK0627429T3 (da) | 1999-10-11 |
| CA2124999A1 (en) | 1994-12-05 |
| JPH06345762A (ja) | 1994-12-20 |
| CA2124999C (en) | 2004-08-10 |
| FI942631A0 (fi) | 1994-06-03 |
| ES2129106T3 (es) | 1999-06-01 |
| KR950000703A (ko) | 1995-01-03 |
| FI108133B (fi) | 2001-11-30 |
| FI942631A (fi) | 1994-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU799666A3 (ru) | Способ получени гидратированной крис-ТАлличЕСКОй фОРМы НАТРиЕВОй СОли 3-АцЕТОКСи-МЕТил-7 2-(2-АМиНО-4-ТиАзОлил)-2-МЕТОКСи-иМиНОАцЕТАМидО цЕф-3-EM-4-КАРбОНОВОй КиС-лОТы,СиН-изОМЕРА | |
| CA2124999C (en) | Loracarbef isopropanolate and a process for converting loracarbef isopropanolate to loracarbef monohydrate | |
| AU711228B2 (en) | Production of cefotaxime and new sodium salts | |
| US4977257A (en) | DMF solvates of a β-lactam antibiotic | |
| AU614440B2 (en) | Solvates of beta-lactam antibiotic | |
| GB2132616A (en) | Improvements in or relating to novel cephalosporin intermediates | |
| US5580977A (en) | Process for preparing loracarbef monohydrate | |
| IL39061A (en) | Method of preparing nitrobenzyl mesylates and tosylates | |
| US5550231A (en) | Loracarbef hydrochloride C1-C3 alcohol solvates and uses thereof | |
| EP0627430B1 (en) | Process for converting loracarbef dihydrate to loracarbef monohydrate | |
| GB1593911A (en) | Cephalosporins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |